MRESVIA Trademark

Trademark Overview

On Tuesday, January 17, 2023, a trademark application was filed for MRESVIA with the United States Patent and Trademark Office. The USPTO has given the MRESVIA trademark a serial number of 97757619. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Monday, November 18, 2024. This trademark is owned by ModernaTx, Inc.. The MRESVIA trademark is filed in the Pharmaceutical Products category with the following description:

vaccines for human use

General Information

Serial Number97757619
Word MarkMRESVIA
Filing DateTuesday, January 17, 2023
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateMonday, November 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 7, 2023

Trademark Statements

Goods and Servicesvaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 7, 2023
Primary Code005
First Use Anywhere DateMonday, July 29, 2024
First Use In Commerce DateMonday, July 29, 2024

Trademark Owner History

Party NameModernaTx, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameModernaTx, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Friday, January 20, 2023NEW APPLICATION ENTERED
Tuesday, February 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 10, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, August 10, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, August 10, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 10, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 10, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 30, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 30, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 30, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 30, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 30, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 29, 2023ASSIGNED TO EXAMINER
Friday, September 29, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 18, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 7, 2023PUBLISHED FOR OPPOSITION
Tuesday, November 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, March 31, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, March 31, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, March 31, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, March 31, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, March 31, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 9, 2024SOU EXTENSION 1 FILED
Thursday, May 9, 2024SOU EXTENSION 1 GRANTED
Thursday, May 9, 2024SOU TEAS EXTENSION RECEIVED
Friday, May 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 31, 2024TEAS STATEMENT OF USE RECEIVED
Friday, September 6, 2024SOU EXTENSION 2 FILED
Friday, September 6, 2024USE AMENDMENT FILED
Friday, September 6, 2024SOU TEAS EXTENSION RECEIVED
Monday, November 18, 2024SOU EXTENSION 2 GRANTED
Monday, November 18, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, November 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 18, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL

Related Keywords

mresvia human vaccines